-
Patent claims RSV fusion protein inhibitors as medicines including
lead pipeline candidate, RV521; patent nominally expires in 2035
(unextended) -
The counterpart to this patent has been issued in Europe and is
pending prosecution in other key territories -
Patent significantly adds to IP portfolio protecting ReViral’s
differentiated pipeline -
Company continues to progress RV521 into international, pediatric
Phase IIa clinical trials during 2019
LONDON–(BUSINESS WIRE)–ReViral Ltd., a clinical-stage company focused on developing novel,
anti-viral compounds that target respiratory syncytial virus (RSV),
today announced that the the United States Patent and Trademark Office
(USPTO) recently granted patent US10,106,539 entitled “Spiro-Indolines
for the Treatment and Prophylaxis of Respiratory Syncytial Virus
Infection (RSV)”. This composition of matter patent claims certain
inhibitors of the fusion protein of the respiratory syncytial virus
(RSV), including RV521, the Company’s lead pipeline asset. The
counterpart to this patent, EP3204375, has also been issued in Europe.
“The grant of this important patent in the US and Europe protects
certain RSV fusion protein inhibitors discovered by ReViral, including
lead pipeline asset RV521, and underscores the novelty of our RSV
pipeline,” said Dr Eddy Littler, CEO of ReViral. “We look forward to
progressing RV521 into international, pediatric phase II clinical trials
this year, with the ultimate goal of bringing new, effective treatments
for RSV to patients.”
ReViral is progressing its lead drug candidate (RV521), a highly potent
and orally bioavailable potential treatment for RSV infections.
Pre-clinical and clinical studies have shown that RV521 is a
best-in-class inhibitor of RSV in adult volunteers. RV521 is now poised
to enter an international multicentre Phase IIa pediatric trial. This
study will be followed by additional trials in adult stem cell
transplant patients.
RSV is one of the most important respiratory pathogens, with 30 million
infections and an estimated 200,000 deaths worldwide annually in
children under five years alone. There are currently no approved RSV
vaccines available, and there is an urgent need for improved
therapeutics for this indication.
Notes to Editors
About ReViral
ReViral is a clinical-stage company focused on developing novel,
anti-viral compounds that target respiratory syncytial virus (RSV).
Founded in 2011, ReViral has an experienced R&D leadership team with a
successful track record in antiviral drug discovery and development. The
company has developed a novel antiviral programme targeting RSV fusion
with highly potent, orally bioavailable inhibitors, strong drug-like
characteristics and good pharmacokinetic properties offering versatility
in the route of administration. The lead candidate RV521 completed a
Phase IIa study in adult volunteers showing high potency and excellent
safety. The company also has an RSV replication programme at an earlier
stage of development and plans to expand its pipeline. In August 2018,
ReViral completed a $55 million Series B funding round from a group of
leading venture capital investors jointly led by New Leaf Venture
Partners and Novo Ventures, part of Novo Holdings A/S, with additional
new investment from Perceptive Advisors. Existing investors Andera
Partners, OrbiMed and Brace Pharma Capital also participated in the
fundraise.
About RV521
RV521 is an orally available small molecule antiviral fusion inhibitor
being evaluated for the treatment of RSV. RV521 blocks RSV replication
by inhibiting RSV F-mediated fusion of RSV to the host cell. In 2018,
RV521 generated positive results in a Phase IIa RSV challenge study in
healthy adult volunteers, producing statistically significant reductions
in viral load and clinical symptoms. In Phase I clinical studies RV521
showed excellent exposure with no serious adverse events. Pre-clinical
toxicity tests in adult and juvenile species showed RV521 to have an
excellent safety profile with an attractive margin over therapeutic
doses.
About Respiratory Syncytial Virus (RSV)
RSV is a pathogen that infects the human respiratory tract, potentially
leading to bronchiolitis and pneumonia. While most (but not all)
otherwise healthy people recover from the virus, there is an increased
risk of severe disease and death in premature infants, individuals with
certain pulmonary conditions, the elderly and those who are immune
suppressed. Globally RSV is responsible for more than 30 million
infections every year and as many as 200,000 infant deaths. An estimated
2-3% of all infants under 2 years of age are hospitalised with RSV.
For more information, please visit http://www.reviral.co.uk
Contacts
ReViral Ltd
Eddy Littler, CEO
E: elittler@reviral.co.uk
T:
+44 (0) 1438 906761
FTI Consulting (PR Advisors to ReViral)
Irma Gomez-Dib (US)
+1 212 850 5761
Simon Conway (UK) +44 20 3727 1000
Email: reviral@fticonsulting.com